MD Anderson   

If so, when and to what extent? 

In the setting of the recent TailorRx data, would these patients be considered more high risk?

If CCRT is pursued, would you move forward with durvalumab consolidation? Assume the patient with ECOG PS 0 and no co-morbidities. How might this chan...

Do you feel differently about using these in patients with a history of HR-negative breast cancer?

Based on subgroup analysis, do you have a preference for cisplatin over carboplatin? 

MonarchE trial criteria includes "patients with four or more positive nodes, or one to three nodes and either tumor size ≥ 5 cm, histologic grade 3...

Does your management change if symptomatic or asymptomatic?

Total neoadjuvant therapy (TNT) included FOLFOX x 4 months and concurrent chemo-RT

Previously untreated

Patient previously received neoadjuvant ddAC-T with residual disease at surgery, followed by adjuvant capecitabine which was completed 2 months prior ...

ER <1%; PR 45%, Her2 negative by IHC and FISH. Grade 3, Ki67: 80%.

Patient was on tamoxifen when progression occurred; unable to tolerate adjuvant AI.

How would this affect adjuvant radiation plan in breast conservation therapy patients and mastectomy patients?

Would you choose to incorporate HER2-targeting agents, chemotherapy, endocrine therapy, or a mix of these?

Do features such as nodal involvement, Ki-67, degree of ER positivity, etc. change your management? Would you use any gene expression assays to help y...

How would you approach additional systemic therapy? Would the clinical stage of the cancer affect your management?

What is your specific therapy choice and duration?

 Would you consider gene profiling to determine need for chemotherapy?

Patient had a clinical T2N0 cancer at diagnosis, completed 6 cycles TCHP, and had 0.2mm residual disease with 80% cellularity, negative sentinel node.

For example, if a patient had testosterone pellets injected, perhaps making endocrine therapy less efficacious, would that sway you to use chemo?

Do your recommendations differ if patients are pre or postmenopausal given the data?

How applicable is the SOFT/TEXT data in this setting ?

How often will you monitor it? In the setting that patient is morbidly obese, does your strategy change?

I.e. either for treatment of high-risk disease or intolerance/contraindication to tamoxifen. Will you continue it for the full 5 year course?

Do you prefer doing this through a "neoadjuvant" approach vs. post-operatively? CALOR trial

In a patient with isolated leptomeningeal disease (no systemic disease), would you still recommend systemic therapy?

Do you reserve this approach for only women with triple negative breast cancer or all-comers?

At what point do you send these test, and in what instances do the results influence your treatment recommendations?